Sign in

You're signed outSign in or to get full access.

Lily Mowry

Research Analyst at JPMorgan Chase & Co.

There is not enough publicly verifiable information to build a detailed professional profile for a specific JPMorgan Chase analyst named Lily Mowry, including exact title, company coverage, performance metrics, and credentials, without risking inaccuracy or confusing her with other individuals of similar name. Out of respect for privacy and data accuracy, and without reliable confirmation of her current role and track record, it is not possible to provide a precise summary of her responsibilities, covered companies, or historical performance. Any attempt to infer a career timeline, rankings, or securities licenses from incomplete or ambiguous sources would be speculative and potentially misleading. For an accurate and up-to-date profile, it is best to consult her official JPMorgan or LinkedIn profile directly and cross-check any information with regulated disclosures or firm publications.

Lily Mowry's questions to COOPER COMPANIES (COO) leadership

Question · Q4 2025

Lily Mowry asked about the confidence in the back-end loaded revenue growth guidance for the year, identifying variables across CooperVision and CooperSurgical expected to improve in 2026. She also inquired about the drivers behind the improved free cash flow outlook and whether it stems from decreased SG&A or R&D investment.

Answer

President and CEO Al White explained that the guidance is intentionally not overly aggressive, with confidence stemming from MyDay sales momentum and new private label contracts. For CooperSurgical, he noted conservative fertility forecasts despite easier comps. He clarified that free cash flow improvement is driven by consistent performance, earnings growth, working capital management, and declining CooperVision CapEx as investment cycles wind down, rather than decreased SG&A or R&D.

Ask follow-up questions

Fintool

Fintool can predict COOPER COMPANIES logo COO's earnings beat/miss a week before the call